Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 12/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.41 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | BCL6 | P41182 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30171940 | 0.96 | PTK6 (0.51) | PTK6EGFRERBB2LCKAURKB | |
| SCHEMBL22122928 | 0.96 | PTK6 (0.51) | PTK6EGFRERBB2LCKAURKB | |
| SCHEMBL22123217 | 0.94 | PTK6 (0.48) | PTK6EGFRERBB2LCKAURKB | |
| SCHEMBL22122922 | 0.93 | PTK6 (0.43) | PTK6KDM4EGAASMN1; SMN2EGFR | |
| SCHEMBL30171553 | 0.93 | PTK6 (0.43) | PTK6KDM4EGAASMN1; SMN2EGFR | |
| SCHEMBL22123032 | 0.91 | PTK6 (0.48) | PTK6KDM4EGAASMN1; SMN2EGFR | |
| SCHEMBL25444479 | 0.91 | PTK6 (0.42) | PTK6KDM4EGAASMN1; SMN2AURKB | |
| SCHEMBL24870892 | 0.90 | PTK6 (0.43) | PTK6KDM4EGAASMN1; SMN2EGFR | |
| SCHEMBL30171755 | 0.90 | PTK6 (0.43) | PTK6KDM4EGAASMN1; SMN2EGFR | |
| SCHEMBL22123977 | 0.89 | PTK6 (0.44) | PTK6EGFRERBB2AURKBHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | claimed |